Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Miles Capital Inc.
Miles Capital Inc. increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.8% during the first quarter, Holdings Channel reports. The firm owned 1,136 shares of the biopharmaceutical company’s stock after buying an additional 425 shares during the period. Miles Capital Inc.’s holdings in Regeneron Pharmaceuticals were worth $440,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of REGN. Korea Investment CORP increased its position in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the period. WFG Advisors LP increased its position in shares of Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,415 shares during the period. Alpha Windward LLC increased its position in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the period. Welch & Forbes LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $211,000. Finally, Comerica Securities Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $213,000. Hedge funds and other institutional investors own 66.90% of the company’s stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 517.33 on Monday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $519.65. The company has a 50-day moving average price of $456.19 and a 200 day moving average price of $393.90. The firm has a market capitalization of $54.62 billion, a P/E ratio of 62.62 and a beta of 1.53. Regeneron Pharmaceuticals also was the recipient of some unusual options trading on Friday. Stock traders bought 1,150 put options on the stock. This represents an increase of 496% compared to the average daily volume of 193 put options.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.42. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.57 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post $12.68 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/06/26/regeneron-pharmaceuticals-inc-regn-shares-bought-by-miles-capital-inc.html.
Several equities analysts recently weighed in on REGN shares. Vetr upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 price target on the stock in a report on Wednesday, March 15th. BMO Capital Markets reiterated a “hold” rating and issued a $412.00 price target (up previously from $408.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 28th. Leerink Swann reiterated an “outperform” rating on shares of Regeneron Pharmaceuticals in a report on Monday, March 20th. Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the stock from $375.00 to $484.00 in a report on Friday, May 5th. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price target on the stock in a report on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $443.49.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,000 shares of the company’s stock in a transaction dated Wednesday, March 29th. The stock was sold at an average price of $400.00, for a total transaction of $400,000.00. Following the completion of the sale, the director now directly owns 1,000 shares in the company, valued at $400,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total value of $4,423,360.30. Following the sale, the executive vice president now owns 43,950 shares of the company’s stock, valued at $23,405,572.50. The disclosure for this sale can be found here. Insiders sold 60,396 shares of company stock valued at $28,884,734 over the last quarter. Insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.